|
|
|
|
Vol. 60, Issue 2, 373-381, August 2001
Portland Veterans Affairs Medical Center and Department of Behavioral Neuroscience, Oregon Health Sciences University, Portland, Oregon (K.A.N., K.R.T., D.C.B.); Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana (M.G.C., V.J.W.); ENRM Veterans Affairs Medical Center, Bedford, Massachusetts (C.J.D.); and Merkert Chemistry Center, Boston College, Chestnut Hill, Massachusetts (M.M.T.)
| |
Abstract |
|---|
|
|
|---|
A homology model of the dopamine D2 receptor was constructed based on the crystal structure of rhodopsin. A putative sodium-binding pocket identified in an earlier model (PDB 1I15) was revised. It is now defined by Asn-419 backbone oxygen at the apex of a pyramid and Asp-80, Ser-121, Asn-419, and Ser-420 at each vertex of the planar base. Asn-423 stabilizes this pocket through hydrogen bonds to two of these residues. Highly conserved Asn-52 is positioned near the sodium pocket, where it hydrogen-bonds with Asp-80 and the backbone carbonyl of Ser-420. Mutation of three of these residues, Asn-52 in helix 1, Ser-121 in helix 3, and Ser-420 in helix 7, profoundly altered the properties of the receptor. Mutants in which Asn-52 was replaced with Ala or Leu or Ser-121 was replaced with Leu exhibited no detectable binding of radioligands, although receptor immunoreactivity in the membrane was similar to that in cells expressing the wild-type D2L receptor. A mutant in which Asn-52 was replaced with Gln, preserving hydrogen-bonding capability, was similar to D2L in affinity for ligands and ability to inhibit cAMP accumulation. Mutants in which either Ser-121 or Ser-420 was replaced with Ala or Asn had decreased affinity for agonists (Ser-121), but increased affinity for the antagonists haloperidol and clozapine. Interestingly, the affinity of these Ser-121 and Ser-420 mutants for substituted benzamide antagonists showed little or no dependence on sodium, consistent with our hypothesis that Ser-121 and Ser-420 contribute to the formation of a sodium-binding pocket.
| |
Introduction |
|---|
|
|
|---|
The
dopamine D2 receptor belongs to a subfamily of
7-transmembrane domain (TM) G protein-coupled receptors that interact
with the G proteins G
i and
G
o to modulate several effectors, including adenylate cyclase and potassium channels (Limbird, 1988
). A
characteristic of G
i-coupled receptors is that
they are regulated by sodium, which decreases the affinity of the
receptors for agonists (Pert and Snyder, 1974
; Limbird et al., 1982
).
Sodium inhibits the binding of agonists by acting directly on the
receptor (Limbird et al., 1982
; Urwyler, 1989
) at a site that is
accessible from the intracellular surface of the cell membrane
(Motulsky and Insel, 1983
; Nunnari et al., 1987
). Although the binding
of antagonist ligands to some G
i-coupled
receptors is modestly enhanced (<10-fold) by sodium (Limbird et al.,
1982
), the D2 receptor is unusual in that the affinity of certain antagonists, most of them substituted benzamide derivatives, is enhanced 10- to 40-fold by sodium (Stefanini et al.,
1980
; Neve, 1991
).
Homology modeling of the dopamine D2 receptor
(Teeter et al., 1994
) has suggested the presence of a pyramidal
sodium-binding pocket defined by residues
Asp-802.50, Ser-1213.39,
Asn-1243.42, and
Ser-4207.46 at each vertex of the base, and
Asn-4237.49 at the apex.
Asn-521.50 is positioned near the sodium pocket,
where it could interact with Asp-80. This putative sodium regulatory
site is contiguous with a proposed nonpolar binding pocket; an
attractive hypothesis is that drugs that occupy the nonpolar binding
pocket may be particularly sensitive to the binding of sodium to the
regulatory site (Teeter et al., 1994
; Teeter and DuRand, 1996
).
Mutation of Asp-80 of the D2 receptor and the
corresponding residue in the
2A-adrenergic
receptor, one of the putative sodium pocket residues, abolishes
regulation of these receptors by sodium (Horstman et al., 1990
; Neve et
al., 1991
). This highly conserved TM2 residue has been a frequent
target of mutagenesis studies, having been mutated in at least 31 different receptor subtypes (Beukers et al., 1999
). In addition to
eliminating regulation of receptors by sodium (Horstman et al., 1990
;
Neve et al., 1991
; Barbhaiya et al., 1996
; Martin et al., 1999
),
mutation of this residue eliminates or greatly reduces functional
coupling of many receptors to G proteins and second messengers (Chung
et al., 1988
; Fraser et al., 1989
; Neve et al., 1991
; Perlman et al.,
1997a
; Donnelly et al., 1999
; Martin et al., 1999
). Thus, binding of sodium to this residue may be important for stabilizing an active receptor conformation.
We now describe a revised D2 receptor model, derived from the newly determined X-ray structure of rhodopsin, in which Asn-4197.45 replaces Asn-124 at one vertex of the pyramidal sodium-binding pocket and the carbonyl of Asn-419 replaces Asn-423 at the apex. Mutation of three additional residues within this region, Asn-52 in TM1, Ser-121 in TM3, and Ser-420 in TM7, profoundly altered the properties of the receptor. We constructed mutant receptors in which Asn-52 of the rat D2L was replaced with alanine (N52A), leucine (N52L), or glutamine (N52Q), and Ser-121 was replaced with alanine (S121A), asparagine (S121N), or leucine (S121L). The mutants N52A, N52L, and S121L exhibited no detectable binding of radioligands, although receptor targeting to the plasma membrane did not appear grossly impaired. The mutant N52Q, which retains hydrogen-bonding capability at this residue, was similar to the wild-type receptor in affinity for ligands and ability to inhibit adenylate cyclase. S121A and S121N had decreased affinity for agonists but increased affinity for the antagonists haloperidol and clozapine. Interestingly, the binding of substituted benzamide antagonists to S121A and S121N showed a loss of sodium sensitivity, with decreased binding compared with wild-type D2L only in the presence of sodium. A similar loss of sodium sensitivity was observed for Ser-420 mutants (S420A, S420N, S420L, and S420V) but not for mutants of a residue now predicted to be oriented away from the putative sodium-binding pocket, Asn-124 (N124A, N124L, N124Q).
| |
Experimental Procedures |
|---|
|
|
|---|
Materials. [3H]Spiperone was purchased from Amersham Pharmacia Biotech (Arlington Heights, IL). [3H]cAMP and [3H]YM09151-2 were from PerkinElmer Life Science Products (Boston, MA). (+)-Butaclamol, clozapine, haloperidol, spiperone, sulpiride, quinpirole, 7-OH-DPAT, pergolide, bromocriptine, and lisuride were purchased from Sigma/RBI (Natick, MA). Tropapride and YM09151-2 were obtained from the National Institute of Mental Health Chemical Synthesis and Drug Supply Program. Epidepride was a generous gift from Dr. T. de Paulis (Vanderbilt University, Nashville, TN). Serum was from HyClone (Logan, UT). Most other reagents, including culture media and dopamine, were purchased from Sigma Chemical Co. (St. Louis, MO).
D2 Receptor Homology Modeling.
An initial
model of the D2 receptor was built from the
two-dimensional electron microscopy structure of bacteriorhodopsin, as
described previously (Teeter et al., 1994
). In brief, based on the
three-dimensional bacteriorhodopsin structure obtained experimentally
and related adrenergic receptor ligand binding mutagenesis, rhodopsin
was aligned with bacteriorhodopsin. Alignment of low homology sequences
was aided by establishing polar and nonpolar helix faces via helical
wheels. From the alignment, D2 receptor residues
were substituted into the coordinates of bacteriorhodopsin (Henderson
et al., 1990
) to build an initial data-based D2
receptor model. Local geometry optimization, Pro template replacements, and side chain rotation consistent with protein structure knowledge refined this model (1I15 in the Protein Data Bank). Global energy
minimization was not used for the final model for reasons discussed
previously (see footnote 1 in Teeter et al., 1994
).
-carbon containing residues in
D2 in this region. Thus, one might expect some
steric hindrance. The backbone torsions (
,
angles) of residues
around the new Pro, particularly the four residues N-terminal to it
(residues i to i-4), were adjusted to relieve the close contacts with
TM3. These changes made the helix more regular (near
60°,
40° in
,
) and accommodated the Pro side chain
No energy minimization was performed nor were molecular dynamics run.
This is in concert with our earlier modeling (Teeter et al., 1994Production of Cell Lines. Mutants of the rat D2L receptor were constructed using the QuikChange mutagenesis kit (Stratagene, La Jolla, CA). Wild-type and mutant receptors in pcDNA3.1 were stably expressed in HEK293 cells by calcium phosphate precipitation, and clonal cell lines were isolated after selection with G418 (800 µg/ml). Cell lines were maintained in Dulbecco's modified Eagle's medium supplemented with 5% iron-supplemented calf bovine serum, 5% fetal bovine serum, 600 µg/ml G418, 0.05 U/ml penicillin, and 50 µg/ml streptomycin at 37°C and 10% CO2.
Immunocytochemical Detection of the D2 Receptor. Cells grown on glass coverslips were fixed in 4% paraformaldehyde/phosphate-buffered saline (58 mM Na2HPO4, 17 mM NaH2PO4, and 68 mM NaCl, pH 7.4) for 15 min, permeabilized in 0.5% Triton X-100 for 15 min, then blocked with 5% goat serum for 1 h at room temperature. Cells were incubated with rabbit anti-D2 receptor antiserum (AB5084P, 1/500 dilution; Chemicon International, Temecula, CA), washed, and incubated for 1 h with Oregon Green-tagged goat anti-rabbit IgG (1/100 dilution; Molecular Probes, Eugene, OR). The cells were washed, mounted onto a slide with Slowfade (Molecular Probes), and imaged with a Leica SP laser scanning confocal microscope (Leica, Deerfield, IL).
[3H]Spiperone Binding Assay.
Cells were lysed
in ice-cold hypotonic buffer (1 mM Na+HEPES,
pH 7.4, 2 mM EDTA) for 10 min, scraped from the plate, and centrifuged at 18,000g for 20 min. The resulting crude membrane fraction
was resuspended with a Brinkmann Polytron homogenizer (Brinkmann
Instruments, Westbury, NY) at setting 6 for 6 to 10 s in
Tris-buffered saline (50 mM Tris-HCl, pH 7.4, 0.9% NaCl). Membrane
proteins (5-20 µg) were incubated in duplicate for 45 min at 37°C
in a total reaction volume of 1 ml with
[3H]spiperone at concentrations ranging from
0.006-0.2 nM for saturation binding or ~0.1 nM with the appropriate
concentration of the competing drug for competition binding.
(+)-Butaclamol (2 µM) was used to define nonspecific binding. In some
experiments, binding in sodium-free buffer was compared with binding in
the presence of 50 mM NaCl. Data for saturation and displacement
binding were analyzed by nonlinear regression using the computer
program Prism (GraphPad, San Diego, CA) to determine
KD and IC50 values.
Apparent affinity (KI) values were
calculated from the IC50 value by the method of
Cheng and Prusoff (1973)
. The free concentration of radioligand was
calculated as the concentration added minus the concentration specifically bound.
cAMP Accumulation Assay.
The ability of
D2 receptor agonists to inhibit 30 µM
forskolin-stimulated cAMP accumulation was measured in intact cells. Cells were plated at a density of 18,000 cells/cm2 in 48-well tissue culture plates and
used in experiments 2 to 3 days later. Before the assay, cells were
preincubated with Earle's balanced salt solution with 0.2% ascorbic
acid and 2% calf bovine serum, pH 7.4, for 10 min at 37°C. The assay
was terminated after 10 min by decanting the medium, and the cells were
placed on ice and lysed with 3% trichloroacetic acid. Lysates were
incubated on ice at least 30 min before cAMP accumulation was measured
using a competitive protein binding assay as described previously
(Watts and Neve, 1996
). Dose-response data were analyzed as described above for radioligand binding.
| |
Results |
|---|
|
|
|---|
Based on the crystal structure of rhodopsin (1F88 in the Protein
Data Bank; Palczewski et al., 2000
) a new model of the dopamine
receptor was constructed (Fig. 1A; Teeter
and DuRand, unpublished observations). In this model, the
sodium-binding pocket is similar to that in the previous model (Teeter
et al., 1994
), except that Asn-1243.42 is pointed
away from the sodium site and hydrogen-bonds to
Ser-752.45 at the back side of tilted TM3.
Conserved residue Asn-4197.45 is now in the
sodium-binding site, which has a pyramidal shape defined by side chain
atoms of Asp-802.50,
Ser-1213.39, Asn-419, and
Ser-4207.46 at each vertex of the planar base,
and the carbonyl oxygen of Asn-419 at the apex (Fig. 1B).
Asn-4237.49 stabilizes the pyramid by
hydrogen-bonding to Asp-80 and to the carbonyl oxygen of
Asn-419. In addition, the Asn-521.50 side chain
hydrogen-bonds to Asp-80 (Fig. 2A)
without changing rotamers, although a rotamer change had been
proposed previously (Teeter et al., 1994
), and it also binds to the
backbone carbonyl of Ser-420 on TM7. The sodium pocket region thus
involves residues from TM1 (Asn-52), TM2 (Asp-80), TM3 (Ser-121), and
TM7 (Asn-419, Ser-420) (Fig. 3).
|
|
|
Three substitution mutants were constructed for both Asn-52 (N52A,
N52Q, and N52L) and Ser-121 (S121A, S121N, S121L). Wild-type and mutant
receptors were stably expressed in HEK293 cells and characterized by
saturation analysis of the binding of the D2 receptor antagonist [3H]spiperone. Three of the
mutants retained high affinity for the radioligand, and clonal cell
lines were selected that expressed approximately equal densities of
receptors (Table 1). Membranes from cell
lines expressing the other three mutants (N52A, N52L, and S121L) showed
no detectable specific binding of [3H]spiperone
or a second D2 receptor antagonist,
[3H]YM09151-2 (data not shown). Expression of
N52A, N52L, and S121L in the cell membrane was confirmed by
immunocytochemistry (Fig. 4).
D2 receptor immunoreactivity was present in the
membrane of cells expressing each of the nonfunctional mutants,
although the cell membrane was labeled less sharply and uniformly than
in cells expressing wild-type D2L receptor.
|
|
The affinity of the mutant receptors for agonists and antagonists was
determined by inhibition of the binding of
[3H]spiperone. Whereas N52Q was
indistinguishable from wild-type D2L with regard
to the affinity of all the agonists and antagonists that were tested,
S121A had 4- to 5-fold enhanced affinity for haloperidol and clozapine,
and a significantly decreased affinity for the agonists 7-OH-DPAT and
dopamine (Table 2). Substitution of Asn
for Ser-121 caused a 2-fold increase in the affinity of the receptor
for clozapine and also caused a greater disruption of agonist binding
compared with S121A, so that the affinity of S121N for dopamine,
quinpirole, and 7-OH-DPAT was decreased 10-, 4-, and 25-fold,
respectively.
|
The affinity and sodium-sensitivity of the binding of four antagonists,
piquindone (Teeter and DuRand, 1996
) and three substituted benzamide
derivatives, was determined by inhibition of the binding of
[3H]spiperone in the presence and absence of 50 mM NaCl (Table 3; Fig.
5). The binding of the drugs to wild-type
D2L depended on the presence of sodium; the
affinity of D2L for the compounds was 13- to
48-fold greater in the presence than in the absence of sodium. The
sodium sensitivity of binding to N52Q was similar to that of
D2L, so that the affinity of N52Q for the drugs
was 13- to 106-fold greater in the presence of sodium. On the other hand, the sodium sensitivity of the binding of these antagonists to
S121A and S121N was greatly reduced, so that affinities for the drugs
were enhanced only 2- to 5-fold by the presence of sodium and, except
for sulpiride at S121A, were more similar to
KI values of the wild-type receptor
obtained in the absence than in the presence of sodium.
|
|
The ability of agonists to activate the mutant receptors was determined
by measuring inhibition of forskolin-stimulated cAMP accumulation
(Table 4). All three of the mutant
receptors that were capable of binding radioligands with high affinity
also inhibited forskolin-stimulated cAMP accumulation; maximal
inhibition was similar for the mutant and wild-type receptors (~60%
of total accumulation). Consistent with the decreased affinity of S121N for agonists, dopamine and quinpirole were significantly less potent at
inhibition of cyclic AMP accumulation via S121N than the wild-type
receptor.
|
To compare the sodium-binding pockets defined in the earlier homology
model (Teeter et al., 1994
) and the revised model, we constructed
substitution mutants of Ser-420, which is part of the sodium site in
both models, and Asn-124, which was suggested to be part of the sodium
site in the earlier model but is pointed away from the sodium site in
the revised model. All of the mutants bound
[3H]spiperone, in some cases with modestly
decreased affinity compared with wild-type D2L
(Table 1). The affinity of N124A and N124L for most antagonists was
decreased by 2- to 5-fold, whereas the mutation of N124Q was more
deleterious, resulting in decreases in affinity of up to 30-fold (Table
5). Nevertheless, mutation of Asn-124
tended to decrease the potency of sodium-sensitive drugs whether or not
sodium was present, so that the magnitude of the sodium-dependent
increase in affinity for substituted benzamide antagonists was similar
for wild-type D2L and all three Asn-124 mutants.
In contrast, all four mutants of Ser-420 (S420A, S420L, S420N, and
S420V) displayed a loss of affinity for substituted benzamide
antagonists that was greater in the presence of sodium than in its
absence, so that the effect of sodium on the binding of these
antagonists was abolished (Table 6). As
observed for Ala and Asn mutants of Ser-121, the affinity of S420A and
S420N for clozapine and haloperidol was increased 2- to 9-fold compared with wild-type D2L.
|
|
| |
Discussion |
|---|
|
|
|---|
A D2 receptor model was built based on the
crystal structure of rhodopsin (Palczewski et al., 2000
). When this
model is viewed from the perspective of the arrow in Fig. 1A, a cluster
of highly conserved polar residues that form a roughly pyramidal region is apparent. This pyramid is defined by
Asp-802.50, Ser-1213.39,
Asn-4197.45, and
Ser-4207.46 at each vertex of the base, and
Asn-419 backbone oxygen at the apex (Fig. 1B). A sodium ion at the
center of this site could form nearly ideal interactions, neutralizing
the negative charge in this region. Four of these interactions appear
to be closer (~3 Å) than the others (~4 Å). This differs from the
previous model (Teeter et al., 1994
) in several ways. First, conserved Asn-4237.49, the former apex, appears to be in
sodium's second coordination shell (~4 Å away). Asn-423 stabilizes
the pocket by hydrogen-bonding to the new apex, the carbonyl oxygen of
Asn-419, as well as to the side chain of Asp-80 at one vertex. Asn-419
is found one turn away from the highly conserved NP sequence (Asn-423,
Pro-4247.50 in D2L), at a
potentially conserved bend in TM7 (Fu et al., 1996
). This bend frees
the Asn-419 carbonyl oxygen to hydrogen-bond to the sodium ion. Second,
Asn-1243.42 has been replaced by Asn-419 at one
of the vertices. Asn-124 is pointed away from the sodium site and
hydrogen bonds to Ser-752.45. In rhodopsin, the
corresponding hydrogen bonding pair is Asn-78 on TM2 and Ser-127 on TM3
(Palczewski et al., 2000
), suggesting that this is a conserved
interaction. Third, the side chains of Asn-419 and Ser-420 are
hydrogen-bonded, further strengthening the sodium-binding pocket.
Finally, the Asn-521.50 side chain hydrogen-bonds
to Asp-80 (Fig. 2A), without changing rotamers as previously proposed
(Teeter et al., 1994
), and also binds to the backbone carbonyl of
Ser-420 on TM7. Both of these interactions as well as the exposed
carbonyl of Asn-419 are conserved in the rhodopsin crystal structure
(Palczewski et al., 2000
) and are likely to be conserved in all G
protein-coupled receptors.
We constructed mutants in which conservative or nonconservative substitutions were made for each of two polar amino acid residues postulated to contribute to the formation of the sodium-binding pocket (Ser-121 and Ser-420) for one residue thought to hydrogen-bond with the highly conserved aspartate residue Asp-80 (Asn-52) and for one residue that was predicted to be part of the sodium-binding pocket in our earlier model, but not in the revised model (Asn-124). Three of the six mutants, N52L, N52A, and S121L, were not detectable by radioligand binding, suggesting that the structure of the D2 receptor is very sensitive to changes in the properties of the residues at these positions. Residues with nonpolar side chains, in particular, were not well tolerated. Immunocytochemical localization of the nonfunctional mutant receptors suggested that each was expressed and targeted to the cell membrane, although the mutant receptors may have been distributed less homogenously around the perimeter of the cell than was the wild-type D2 receptor. Although conclusive demonstration of appropriate cell membrane targeting would require labeling of nonpermeabilized cells with an antibody directed against an extracellular epitope, the immunocytochemical data demonstrate the synthesis of D2 receptor protein from the transfected plasmid.
The D2L receptor mutant N52Q was
indistinguishable from wild-type D2L with regard
to the potency of agonists and antagonists, sensitivity to sodium, and
inhibition of forskolin-stimulated cyclic AMP accumulation. In our
model, this is explained by the ability of Gln to preserve the
postulated hydrogen-bonding interaction of the native Asn-52 with
Asp-80 (Fig. 2B). Interaction of Asn1.50 with
Asp2.50 is also predicted by models of the TRH
and
1B-adrenergic receptors, with mutagenesis
data that support the interaction (Scheer et al., 1996
; Perlman et al.,
1997a
). Interestingly, substitution of Ala or Asp for
Asn1.50 in the TRH receptor (N43A and N43D) or
the
1B-adrenergic receptor (N63A and N63D) has
less severe consequences than substitution with Ala or Leu in the
D2 receptor in the present study. In the case of
the TRH receptor, the mutants are detectable by ligand binding and are
functional, albeit with reduced affinity for ligands, decreased density
of expression, and decreased ability to stimulate inositol phosphate
formation (Perlman et al., 1997a
). N63A and N63D mutants (but not N63L
or N63F mutants) of the
1B-adrenergic receptor
also bind agonist and antagonist ligands with high affinity and
stimulate inositol phosphate formation (Scheer et al., 1996
). Studies
of the tachykinin NK2 receptor suggest that the
primary effect of mutation of Asn1.50 to Asp or
His (N51D and N51H) is to greatly reduce the expression of the
receptors, without markedly altering the binding of ligands or
functional coupling (Donnelly et al., 1999
). Similarly, an N33A1.50 mutant of the platelet activating factor
receptor binds agonist and antagonist radioligands (Ishii et al.,
1997
). In the case of the peptide receptors, the less severe
consequences of substituting Ala at this position, compared with the
consequences for the D2L receptor, could be
caused by a different mode of ligand binding, which is primarily to the
extracellular loops rather than to the transmembrane helices, but it is
not clear why the Ala substitution at this position is better tolerated
by the
1b-adrenergic receptor (Scheer et al.,
1996
) than by the D2L receptor (present results).
The deleterious consequences of the N52A substitution compared
with the sparing of function in S121A is interesting. Ser-121 is part
of the sodium site, which is an open cavity with considerable water
around. Indeed, a water molecule is at the center of a site in the
rhodopsin structure that corresponds to the presumed sodium-binding site in the D2 receptor (Palczewski et al.,
2000
). Thus, the sparing of function after replacement of Ser-121 with
a nonpolar alanine residue in S121A is probably caused by a polar water
molecule filling the space vacated by the lost hydroxyl of the serine
side chain (Alber et al., 1987
). On the other hand, in our model,
Asn-52's site has no cavity for water and is quite "tight" but
hydrophilic, and the Ala substitution would therefore be more deleterious.
In addition to binding sodium, the polar pocket formed by
Asn1.50, Asp2.50, and
Asn7.49 (Asn-423 in the D2L
receptor) has been postulated to be involved in regulating the
equilibrium between active and inactive receptor conformations (Scheer
et al., 1996
). According to this model, Arg3.50
of the highly conserved Asp-Arg-Tyr (DRY) sequence at the base of TM3
is stabilized within the polar pocket by hydrogen-bonding and
electrostatic interactions with Asn1.50 and
Asp2.50, and mutation of
Asn1.50 shifts Arg3.50 out
of the polar pocket, mimicking the active conformation of the receptor.
However, in the rhodopsin crystal structure (Palczewski et al., 2000
)
and in our new D2 receptor model, the distance
between Arg3.50 in the DRY (or ERY) sequence and
either Asn1.50 or Asp2.50
is about 20 Å. Instead of interacting with TM1 and TM2,
Arg3.50 in the ERY in rhodopsin has a salt link
with Glu-3696.30 (D2L
numbering) in the TM6 helical extension.
The S121A and S121N mutants of the D2L
receptor differed from the wild-type receptor in several respects. The
affinity of the receptors for some antagonists (clozapine and
haloperidol) was enhanced modestly, whereas there was a moderate
decrease in affinity for several agonists. Both mutant receptors
mediated agonist inhibition of adenylate cyclase, with decreases in
agonist potency that roughly paralleled the decreased agonist affinity observed in ligand binding studies. The most robust effect of these
mutations was to decrease the sodium sensitivity of the binding of
those antagonists that have markedly higher affinity for the wild-type
D2 receptor in the presence of sodium. As was observed previously for the D80A mutant (Neve et al., 1991
), regardless of the presence or absence of sodium, the affinity of the mutants for
substituted benzamide derivatives was similar to that of the wild-type
receptor in the absence of sodium. Similar results were observed for
Ala and Asn substitutions of Ser-420, whereas Val or Leu substitution
for Ser-420 abolished the sodium sensitivity of the receptor without
increasing the affinity of the mutants for haloperidol and clozapine.
In contrast, mutation of Asn-124 had little effect on the sodium
sensitivity of the D2L receptor, supporting the
revised receptor model in which this residue is not predicted to be
part of the sodium-binding pocket.
The S121N mutation caused decreased binding of benzamides despite
the potential of the Asn to hydrogen-bond to sodium. This could be
explained by direct interference of the larger Asn with the binding of
benzamides. In our model, distances between Asn-121 and benzamide
ligands are approximately 2 Å. Furthermore, the side chains of Asn-121
(TM3) and Asn-423 (TM7) could hydrogen-bond (distance 3.4 Å). In
rhodopsin, TM3 and TM6 are shown to move apart at the interior in the
activated receptor (Farrens et al., 1996
). TM7 also changes its
position later in the rhodopsin photocycle (Kim et al., 1997
). A
hydrogen bond between TM3 and TM7 would constrain this movement.
Ser-1213.39 has been a target in mutagenesis
studies of many G protein-coupled receptors, and a cysteine-scanning
study indicates that the residue is within the water-accessible ligand
binding pocket of the D2 receptor (Javitch et
al., 1995
). Ala mutants of this residue have been reported to not be
expressed (
2-adrenergic receptor; Strader et
al., 1989
), to be expressed but unable to bind ligands (adenosine A1
receptor; Barbhaiya et al., 1996
), or to be expressed and able to bind
ligands but unable to stimulate inositol phosphate accumulation (AT1 receptor; Monnot et al., 1996
). On the other
hand, mutation of this residue to Ala has little or no effect on ligand
binding or receptor signaling for the M1
acetylcholine receptor (Lu and Hulme, 1999
) and the platelet-activating
factor receptor (Ishii et al., 1997
) and little or no effect on ligand
binding for the angiotensin II AT1 receptor
(Monnot et al., 1996
; Perlman et al., 1997b
), the bradykinin
B2 receptor (Jarnagin et al., 1996
), and the
adenosine A2a receptor (Jiang et al., 1996
). The
S123A mutant of the C5a chemotactic peptide receptor is also functional
(Baranski et al., 1999
), as is the S115G mutant of the
AT1 receptor (Noda et al., 1996
). These studies
are all consistent with our observation that mutation of Ser-121 to Ala
or Asn had little effect on the binding of ligands to the
D2L receptor or the ability of the receptor to
inhibit adenylate cyclase, but selectively altered the regulation of
the receptor by sodium.
The question arises whether the sodium pocket, documented to be accessible from the cytoplasmic side only, is permeable to sodium ions in the new D2 receptor model. This might be expected because of the proximity of the nonpolar ligand binding pocket to the water-accessible Ser-121 (see above). However, TM3 is tilted in rhodopsin and in our model, and Met-1163.35 (first M in DVMM) lies to the extracellular side of the sodium pocket, partially blocking the path of sodium to the extracellular side but not occluding Ser-121 from that side. In addition, the nonpolar atoms of the pocket are incompatible with the polar sodium ion but well suited for ligand binding or disulfide bond formation by MTSEA. Although MTSEA has a polar end that demonstrates proximity to water, in cysteine-scanning studies, the alkyl sulfide end could access the Ser-121 site that has been mutated to the less polar Cys through the pocket. Thus, our model is consistent with these residues forming a sodium-binding pocket, as opposed to a pore or channel.
Mutation of the residue corresponding to
Ser-4207.46 to Ala had little effect on ligand
binding to the
2-adrenergic receptor (Strader
et al., 1989
) or the P2Y1 purinoceptor (Jiang et
al., 1997
), whereas the same mutation decreased the affinity of the 5HT1A receptor (S393A) for agonists (Chanda et
al., 1993
) and the affinity of the adenosine A2A
receptor (S281A) for agonist and antagonist ligands. Interestingly, the
conservative substitution S281N7.46 in the
A2A receptor increased receptor affinity for
agonists but not antagonists (Jiang et al., 1996
), whereas in the
present study, the potency of several antagonist ligands for either
S420A or S420N mutants of D2L was enhanced.
Consistent with the present results, the
S391A7.46 mutation of the short form of the
D2 receptor, D2S, has
little effect on the binding of most ligands but decreases the potency of substituted benzamide antagonists in the presence of sodium (Cox et
al., 1992
). Because this residue is not exposed to the water-accessible
ligand binding crevice (Fu et al., 1996
), effects of mutation of the
residue on ligand affinity are probably indirect.
Asn-1243.42 is not within the
water-accessible ligand binding pocket of the D2
receptor (Javitch et al., 1995
), and probably does not participate
directly in the binding of ligands. The effects of mutation of this
residue on ligand binding are probably secondary to disruption of helix
packing. In this regard, it is interesting that replacing the polar Asn
side chain with a polar but bulkier Gln side chain was more deleterious
than substitution with nonpolar residues that are smaller than or
similar in size to Asn. Mutation of the corresponding residue in the
M1 muscarinic receptor (N115A) has little effect
on the function of that receptor (Lu and Hulme, 1999
).
In summary, these results support our hypothesis that Asn-52 and Ser-121 are crucial for maintaining the conformation of the ligand-binding pocket of the D2L dopamine receptor, because certain nonconservative substitutions result in a profound loss of receptor function. Furthermore, the loss of sensitivity to sodium of the S121A and S121N mutants and all of the Ser-420 substitution mutants is in accord with our prediction that Ser-121 and Ser-420 participate in the formation of a sodium-binding pocket on the receptor.
| |
Footnotes |
|---|
Received November 13, 2000; Accepted May 3, 2001
This work was supported by the Department of Veterans Affairs Career Scientist and Merit Review Programs (K.A.N.). The support of the ENRM VA Medical Center in Bedford, MA, and Greg Binus, M.D., at VA Bedford are gratefully acknowledged (C.J.D.). Funding for this project was also provided by National Institutes of Health Grant R01-GM38114 (M.M.T.) and Boston College internal grants. Tropapride was provided by RBI as part of the National Institute on Mental Health Chemical Synthesis Program, Contract NOIMN30003. We thank Hoffman-La Roche Inc. (Dr. Gary Olson) for making the sample of piquindone available to us for this study. Portions of this work were presented previously in abstract form (Soc Neurosci Abstr 1999;25:955).
Dr. Kim A. Neve, VA Medical Center (R&D-30), 3710 SW US Veterans Hospital Rd, Portland, OR 97201. E-mail: nevek{at}ohsu.edu
| |
Abbreviations |
|---|
TM, transmembrane domain; 7-OH-DPAT, hydroxy-2-dipropylaminotetralin; HEK, human embryonic kidney.
| |
References |
|---|
|
|
|---|
-adrenergic receptors: identification of a conserved aspartate residue involved in agonist binding and receptor activation.
J Biol Chem
263:
4052-4055
2-adrenergic receptors by sodium.
J Biol Chem
265:
21590-21595
2-adrenergic receptor in membrane and solubilized preparations.
Mol Pharmacol
21:
609-617[Abstract].
2-adrenergic receptor system of human platelets: Role for intraplatelet sodium in receptor binding.
J Biol Chem
258:
3913-3919
2-adrenergic receptors by Na+, H+, and inhibitors of Na+/H+ exchange.
J Biol Chem
262:
12387-12392
1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation.
EMBO J
15:
3566-3578[Medline].
-adrenergic receptor.
J Biol Chem
264:
13572-13578This article has been cited by other articles:
![]() |
S. S. Ericksen, D. F. Cummings, H. Weinstein, and J. A. Schetz Ligand Selectivity of D2 Dopamine Receptors Is Modulated by Changes in Local Dynamics Produced by Sodium Binding J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 40 - 54. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Oliveira, C. M. Costa-Neto, C. R. Nakaie, S. Schreier, S. I. Shimuta, and A. C. M. Paiva The Angiotensin II AT1 Receptor Structure-Activity Correlations in the Light of Rhodopsin Structure Physiol Rev, April 1, 2007; 87(2): 565 - 592. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Nguyen and V. J. Watts Dexamethasone-Induced Ras Protein 1 Negatively Regulates Protein Kinase C {delta}: Implications for Adenylyl Cyclase 2 Signaling Mol. Pharmacol., May 1, 2006; 69(5): 1763 - 1771. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Lan, C. J. DuRand, M. M. Teeter, and K. A. Neve Structural Determinants of Pharmacological Specificity Between D1 and D2 Dopamine Receptors Mol. Pharmacol., January 1, 2006; 69(1): 185 - 194. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-G. Gao, S.-K. Kim, A. S. Gross, A. Chen, J. B. Blaustein, and K. A. Jacobson Identification of Essential Residues Involved in the Allosteric Modulation of the Human A3 Adenosine Receptor Mol. Pharmacol., May 1, 2003; 63(5): 1021 - 1031. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Okada, Y. Fujiyoshi, M. Silow, J. Navarro, E. M. Landau, and Y. Shichida Functional role of internal water molecules in rhodopsin revealed by x-ray crystallography PNAS, April 30, 2002; 99(9): 5982 - 5987. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Okada, Y. Fujiyoshi, M. Silow, J. Navarro, E. M. Landau, and Y. Shichida Functional role of internal water molecules in rhodopsin revealed by x-ray crystallography PNAS, April 30, 2002; 99(9): 5982 - 5987. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||